Key Points
- Insider Tsveta Milanova sold 2,872 shares on Jan. 5 at $27.02 for $77,601.44 (after the trade she owns 34,793 shares), marking a 7.63% reduction in her stake; she also sold 2,932 shares on Dec. 30.
- Agios stock opened at $28.54 and trades in a 52‑week range of $22.24–$46.00, with a market capitalization of about $1.66 billion and a negative P/E of -4.08.
- The company recently beat quarterly estimates (EPS -$1.78 vs. -$1.93; revenue $12.88M vs. $10.49M, revenue +43.3% YoY) but remains unprofitable, and analysts are mixed—consensus target $39.44 while Goldman Sachs cut its target to $25.
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) insider Tsveta Milanova sold 2,872 shares of the business's stock in a transaction on Monday, January 5th. The shares were sold at an average price of $27.02, for a total transaction of $77,601.44. Following the transaction, the insider owned 34,793 shares of the company's stock, valued at $940,106.86. This trade represents a 7.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Tsveta Milanova also recently made the following trade(s):
- On Tuesday, December 30th, Tsveta Milanova sold 2,932 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $27.09, for a total value of $79,427.88.
Agios Pharmaceuticals Stock Performance
NASDAQ:AGIO opened at $28.54 on Thursday. Agios Pharmaceuticals, Inc. has a 52-week low of $22.24 and a 52-week high of $46.00. The stock has a fifty day moving average of $31.30 and a 200 day moving average of $35.82. The firm has a market capitalization of $1.66 billion, a price-to-earnings ratio of -4.08 and a beta of 0.89.
Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last announced its earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.78) earnings per share for the quarter, topping analysts' consensus estimates of ($1.93) by $0.15. Agios Pharmaceuticals had a negative return on equity of 28.35% and a negative net margin of 895.86%.The business had revenue of $12.88 million for the quarter, compared to analyst estimates of $10.49 million. During the same period in the prior year, the company earned $16.22 EPS. The company's quarterly revenue was up 43.3% compared to the same quarter last year. Equities analysts forecast that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Agios Pharmaceuticals
Several large investors have recently made changes to their positions in the business. AQR Capital Management LLC grew its stake in shares of Agios Pharmaceuticals by 66.8% in the first quarter. AQR Capital Management LLC now owns 51,489 shares of the biopharmaceutical company's stock worth $1,498,000 after acquiring an additional 20,625 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Agios Pharmaceuticals by 7.2% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,327 shares of the biopharmaceutical company's stock valued at $1,274,000 after purchasing an additional 2,920 shares during the period. NewEdge Advisors LLC purchased a new position in shares of Agios Pharmaceuticals in the 1st quarter worth $40,000. Goldman Sachs Group Inc. boosted its position in Agios Pharmaceuticals by 16.1% in the first quarter. Goldman Sachs Group Inc. now owns 658,652 shares of the biopharmaceutical company's stock worth $19,299,000 after purchasing an additional 91,482 shares during the last quarter. Finally, Woodline Partners LP purchased a new position in shares of Agios Pharmaceuticals in the first quarter worth approximately $597,000.
Analyst Ratings Changes
AGIO has been the subject of a number of research analyst reports. The Goldman Sachs Group dropped their price objective on shares of Agios Pharmaceuticals from $40.00 to $25.00 and set a "neutral" rating for the company in a report on Thursday, November 20th. Citigroup reiterated a "buy" rating on shares of Agios Pharmaceuticals in a report on Friday, December 26th. Bank of America increased their price objective on Agios Pharmaceuticals from $32.00 to $34.00 and gave the company a "buy" rating in a research report on Wednesday, December 24th. Weiss Ratings restated a "sell (d)" rating on shares of Agios Pharmaceuticals in a research report on Monday, December 29th. Finally, Leerink Partnrs upgraded shares of Agios Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Thursday, November 20th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $39.44.
Get Our Latest Stock Report on AGIO
About Agios Pharmaceuticals
(
Get Free Report)
Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company's scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.
Agios's lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
